Adempas

(Riociguat)

Adempas

Drug updated on 11/10/2023

Dosage FormTablet (oral; 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg)
Drug ClassSoluble Guanylate Cyclase Stimulators
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adults with persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.
  • For the treatment of adults with pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class, and to delay clinical worsening.

Product Monograph / Prescribing Information

Document TitleYearSource
Adempas (riociguat) Prescribing Information.2023Bayer HealthCare Pharmaceuticals Inc.,Whippany, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: a systematic review and meta-analysis.2023Frontiers in Pharmacology
[Corrigendum]: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.2023Frontiers in Pharmacology
Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension.2022Expert review of Pharmaeconomics & Outcomes research
Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.2022Canadian Respiratory Journal
Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis.2022European Respiratory Review
Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: a meta-analysis.2021Medicine
Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis.2021Annals of Palliative Medicine
An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.2021Arthritis research & therapy
Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: a systematic review and meta-analysis.2020World Journal of Cardiology
Efficacy and safety of the use of pulmonary arterial hypertension pharmacotherapy in patients with pulmonary hypertension secondary to left heart disease: a systematic review.2019Pharmacotherapy
Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis.2019Clinical Cardiology
Influence of riociguat treatment on pulmonary arterial hypertension: A meta-analysis of randomized controlled trials.2019Herz
The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure.2018Medicine

Clinical Practice Guidelines